FIGURE 4 from EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

EphA2-NF is an independent diagnostic biomarker for pancreatic cancer from CA19-9. A and B, The ROC curves of serum EphA2-NF and CA19-9 to differentiate pancreatic cancer and HDs divided into high (A) and low (B) CA19-9 groups. The AUC for the diagnosis of pancreatic cancer by serum EphA2-NF (vs. test cohort HDs) for CA19-9 high or low was 0.87. C, There was no significant correlation between serum EphA2-NF and CA19-9 levels. D, Dot plot analysis of serum EphA2-NF in CA19-9–negative patients. E, ROC curves of serum EphA2-NF for pancreatic cancer with CA19-9 ≤2.0 U/mL.